ANI Pharmaceuticals, Inc. / Fundamentals
Income statement
- Net revenue
€637.49M - Cost of goods sold
€268.07M - Gross profit
€369.42M - SG&A expenses
€261.94M - R&D expenses
€45.95M - EBITDA
€80.56M - D&A
€72.09M - EBIT
€12.96M - Interest expenses
€21.05M - EBT
-€12.58M - Tax expenses
-€3.87M - Net income
-€9.41M
Cash flow statement
- Net deferred tax
-€25.62M - Non-cash items
€25.02M - Changes in working capital
€33.93M - Operating cash flow
€118.68M - Capex
€10.18M - Other investing cash flow
-€17.82M - Net investing cash flow
-€371.85M - Total cash dividends paid
-€1.39M - Issuance of common stock
-€2.01M - Debt repayment
€294.00M - Other financing cash flow
-€41.22M - Net financing cash flow
€234.11M - Foreign exchange effects
€63.12K - Net change in cash
-€19.00M - Cash at end of period
€185.80M - Free cash flow
€128.86M
Balance sheet
- Cash and cash equivalents
€185.77M - Cash and short-term investments
€185.77M - Total receivables
€192.47M - Inventory
€117.98M - Other current assets
€17.80M - Total current assets
€514.01M - Property, plant & equipment
€50.53M - Goodwill
€51.63M - Intangible assets
€443.81M - Long-term investments
€2.39M - Other non-current assets
€4.65M - Total non-current assets
€631.50M - Total assets
€1.15B - Accounts payable
€46.54M - Short-term debt
€11.27M - Other current liabilities
€141.38M - Total current liabilities
€202.01M - Long-term debt
€261.74M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€288.04M - Total non-current liabilities
€549.78M - Total liabilities
€772.98M - Common stock
€1.71K - Retained earnings
-€65.56M - Other equity
€2.82M - Total equity
€372.53M - Total liabilities and shareholders' equity
€1.15B
Company information
- Market capitalization
€1.21B - Employees
897 - Enterprise Value
€1.53B
Company ratios
- Gross margin
-
57.9% Much worse than peer group: 496.6% - EBITDA margin
-
12.6% Much worse than peer group: 56.1% - EBIT margin
-
2.0% Much worse than peer group: 43.8% - EBT margin
-
-2.0% Much better than peer group: -223.3% - Net margin
-
-1.5% Much better than peer group: -195.2% - ROE
-
-2.5% Better than peer group: -22.2% - ROA
-
-0.8% Better than peer group: -6.8% - Asset turnover
-
55.7% Even with peer group: 55.2% - FCF margin
-
17.0% Much better than peer group: -143.5% - FCF yield
9.0% - Efficiency ratio
87.4% - Net sales per employee
-
€710.70K - Net income per employee
-
-€10.49K